Inhaled corticosteroids and pneumonia in chronic obstructive pulmonary disease

Rosa Malo de Molina; Marcos I. Restrepo; Eric M. Mortensen; Jose L. Izquierdo; Antonio Anzueto

doi:10.2174/157339810791526229

Inhaled corticosteroids and pneumonia in chronic obstructive pulmonary disease

Rosa Malo de Molina, Marcos I. Restrepo, Eric M. Mortensen, Jose L. Izquierdo, Antonio Anzueto

Research output: Contribution to journal › Article › peer-review

Abstract

Inhaled corticosteroids (ICS) have been recommended for use in patients with chronic obstructive pulmonary disease (COPD) in order to decrease exacerbation rates and improve health related quality of life parameters. Nevertheless, recent studies have reported an increased risk of pneumonia associated with this treatment. However, most studies were not specifically designed to detect pneumonia as a possible secondary effect and for this reason it is difficult to determine whether this risk exists and assess its magnitude. This paper reviews the published studies reporting pneumonia events in COPD patients treated with ICS.

Original language	English (US)
Pages (from-to)	162-166
Number of pages	5
Journal	Current Respiratory Medicine Reviews
Volume	6
Issue number	3
DOIs	https://doi.org/10.2174/157339810791526229
State	Published - 2010

Keywords

Chronic obstructive pulmonary disease
Inhaled corticosteroids
Pneumonia

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine

Access to Document

10.2174/157339810791526229

Cite this

@article{470a7341536e455892ae87128e88ddd8,

title = "Inhaled corticosteroids and pneumonia in chronic obstructive pulmonary disease",

abstract = "Inhaled corticosteroids (ICS) have been recommended for use in patients with chronic obstructive pulmonary disease (COPD) in order to decrease exacerbation rates and improve health related quality of life parameters. Nevertheless, recent studies have reported an increased risk of pneumonia associated with this treatment. However, most studies were not specifically designed to detect pneumonia as a possible secondary effect and for this reason it is difficult to determine whether this risk exists and assess its magnitude. This paper reviews the published studies reporting pneumonia events in COPD patients treated with ICS.",

keywords = "Chronic obstructive pulmonary disease, Inhaled corticosteroids, Pneumonia",

author = "{de Molina}, {Rosa Malo} and Restrepo, {Marcos I.} and Mortensen, {Eric M.} and Izquierdo, {Jose L.} and Antonio Anzueto",

note = "Funding Information: SLJ has received grant funding and personal fees from Centocor, Sanofi Pasteur, GlaxoSmithKline, Chiesi, Boehringer Ingelheim, Novartis, Grunenthal, and Synairgen. AS has received speakers' honoraria from GlaxoSmithKline. PM has received travel grants and speakers' honoraria for speaking from GlaxoSmithKline and Novartis. LF, MB, and SLE declare no competing interests.",

year = "2010",

doi = "10.2174/157339810791526229",

language = "English (US)",

volume = "6",

pages = "162--166",

journal = "Current Respiratory Medicine Reviews",

issn = "1573-398X",

publisher = "Bentham Science Publishers B.V.",

number = "3",

}

TY - JOUR

T1 - Inhaled corticosteroids and pneumonia in chronic obstructive pulmonary disease

AU - de Molina, Rosa Malo

AU - Restrepo, Marcos I.

AU - Mortensen, Eric M.

AU - Izquierdo, Jose L.

AU - Anzueto, Antonio

N1 - Funding Information: SLJ has received grant funding and personal fees from Centocor, Sanofi Pasteur, GlaxoSmithKline, Chiesi, Boehringer Ingelheim, Novartis, Grunenthal, and Synairgen. AS has received speakers' honoraria from GlaxoSmithKline. PM has received travel grants and speakers' honoraria for speaking from GlaxoSmithKline and Novartis. LF, MB, and SLE declare no competing interests.

PY - 2010

Y1 - 2010

N2 - Inhaled corticosteroids (ICS) have been recommended for use in patients with chronic obstructive pulmonary disease (COPD) in order to decrease exacerbation rates and improve health related quality of life parameters. Nevertheless, recent studies have reported an increased risk of pneumonia associated with this treatment. However, most studies were not specifically designed to detect pneumonia as a possible secondary effect and for this reason it is difficult to determine whether this risk exists and assess its magnitude. This paper reviews the published studies reporting pneumonia events in COPD patients treated with ICS.

AB - Inhaled corticosteroids (ICS) have been recommended for use in patients with chronic obstructive pulmonary disease (COPD) in order to decrease exacerbation rates and improve health related quality of life parameters. Nevertheless, recent studies have reported an increased risk of pneumonia associated with this treatment. However, most studies were not specifically designed to detect pneumonia as a possible secondary effect and for this reason it is difficult to determine whether this risk exists and assess its magnitude. This paper reviews the published studies reporting pneumonia events in COPD patients treated with ICS.

KW - Chronic obstructive pulmonary disease

KW - Inhaled corticosteroids

KW - Pneumonia

UR - http://www.scopus.com/inward/record.url?scp=77958197124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958197124&partnerID=8YFLogxK

U2 - 10.2174/157339810791526229

DO - 10.2174/157339810791526229

M3 - Article

AN - SCOPUS:77958197124

SN - 1573-398X

VL - 6

SP - 162

EP - 166

JO - Current Respiratory Medicine Reviews

JF - Current Respiratory Medicine Reviews

IS - 3

ER -

Inhaled corticosteroids and pneumonia in chronic obstructive pulmonary disease

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this